ORM2-ZG16 Axis Regulates Pancreatic Fibrosis via Autophagy Control

Study Background and Research Question

Chronic pancreatitis (CP) is a progressive fibro-inflammatory disease marked by sustained activation of pancreatic stellate cells (PSCs) and excessive extracellular matrix (ECM) deposition, leading to irreversible pancreatic fibrosis and functional decline. Despite advances in clinical management, current therapies—ranging from enzyme replacement to surgical intervention—fail to address the underlying drivers of fibrogenesis or halt disease progression. A growing body of evidence points to the role of autophagy, a conserved lysosomal degradation pathway, in PSC activation and fibrotic transformation. However, the molecular mechanisms governing autophagic flux in this context remain poorly defined. The reference study (Huang et al., 2026) addresses whether ORM2, an acute-phase protein, modulates pancreatic fibrosis in CP by regulating autophagy in PSCs—and if so, through what downstream mediators.

Key Innovation from the Reference Study

The central advance of this work is the identification of ORM2 as a negative regulator of PSC-mediated fibrosis via modulation of autophagy, specifically through its interaction with the protein ZG16. Previous research has implicated autophagy as a pro-fibrogenic driver in CP; however, the regulatory mechanisms and points of therapeutic intervention were uncertain. By demonstrating that ORM2 directly binds ZG16 and blocks autolysosome formation, the authors reveal a previously unrecognized checkpoint in the fibrogenic process. This mechanistic insight not only refines our understanding of ECM regulation in the pancreas but also highlights potential molecular targets for antifibrotic strategies.

Methods and Experimental Design Insights

The study employs a multi-tiered design integrating in vivo and in vitro models:

• In vivo CP induction: Chronic pancreatitis was modeled in mice via repeated intraperitoneal injections of caerulein, a well-established protocol to stimulate PSC activation and fibrosis (internal review).
• Genetic manipulation: Pancreas-specific ORM2 knockout and overexpression were achieved using adeno-associated virus (AAV)-mediated gene delivery, allowing for controlled modulation of ORM2 levels in the target tissue.
• PSC isolation and activation assay: Primary mouse and human PSCs were isolated and treated with TGF-β1 to induce fibrotic activation in vitro, providing a reductionist system to interrogate direct molecular interactions.
• Autophagic flux analysis: Autophagy was quantified using Western blot analysis for LC3-II/I and p62, transmission electron microscopy to visualize autophagosomes, and an LC3B-RFP-GFP tandem reporter assay to distinguish autophagosome maturation.
• Protein-protein interaction mapping: The SPIDER technique and co-immunoprecipitation (co-IP) assays were used to identify and verify ZG16 as an ORM2-binding partner.

The use of both loss-of-function and gain-of-function mouse models strengthens the causal inference regarding ORM2's role in fibrogenic regulation.

Core Findings and Why They Matter

The principal findings can be summarized as follows:

• ORM2 is differentially regulated in CP: ORM2 expression is significantly decreased in pancreatic tissue but increased in serum and liver during CP progression, suggesting tissue-specific roles and possible compensatory responses.
• ORM2 deficiency exacerbates fibrosis: Pancreas-specific ORM2 knockout in mice led to increased fibrotic marker expression (α-SMA, COL1A1, fibronectin) and greater collagen deposition compared to controls.
• ORM2 overexpression is protective: Transgenic overexpression of ORM2 resulted in attenuated PSC activation, reduced ECM production, and lower fibrosis indices.
• Autophagy modulation is central: ORM2 suppressed TGF-β1-induced autophagic flux in PSCs by inhibiting autolysosome formation, thereby blocking a critical step in PSC activation.
• ZG16 is a key mediator: ORM2 binds directly to ZG16; ZG16 knockout abrogated the antifibrotic effects of ORM2 both in vitro and in vivo, confirming the functional importance of this interaction.

Collectively, these results establish a new autophagy-dependent pathway in the regulation of pancreatic fibrosis and identify ORM2-ZG16 as a critical axis for therapeutic targeting. Emerging evidence from related studies has shown that modulating autophagy in PSCs can induce apoptosis and reduce fibrotic output, further supporting the translational relevance of these findings (see also UCMSC-EV research).

Comparison with Existing Internal Articles

This study's mechanistic focus on the ORM2-ZG16-autophagy axis complements and extends prior literature on pancreatic fibrosis models and experimental tools. For example, earlier protocols using Ceruletide (caerulein), a synthetic decapeptide analog of cholecystokinin, are foundational for establishing CP models and triggering PSC activation in vivo (internal protocol review). While these resources provide detailed guidance on assay design and model reproducibility, the present study uniquely connects upstream acute-phase response proteins (ORM2) with autophagy modulation, thus offering new checkpoints for intervention beyond established injury paradigms. Furthermore, reviews of gastrointestinal physiology studies emphasize the value of robust, high-purity reagents such as Ceruletide for consistent modeling (see further protocol insights), but do not address post-injury molecular regulation as explored here.

Limitations and Transferability

While the study rigorously demonstrates the antifibrotic role of ORM2 via ZG16-mediated autophagy inhibition in murine and cell culture systems, several translational caveats merit consideration:

• Species specificity: The bulk of the mechanistic evidence is derived from mouse models; while human PSCs were included, in vivo validation in human tissue remains outstanding.
• Acute-phase protein complexity: ORM2 is one isoform within the orosomucoid family, and its broader immunometabolic effects in CP or other fibrotic diseases may introduce unforeseen variables.
• Model limitations: Caerulein-induced CP is a widely accepted but artificial model; thus, the spectrum and chronicity of human disease may not be fully recapitulated.

Nevertheless, the pathway delineated in this study provides a robust starting point for further exploration in translational and therapeutic research.

Protocol Parameters

• Caerulein (Ceruletide) induction: 50 µg/kg intraperitoneally, administered 6 times daily at hourly intervals for up to 5 days, is standard for murine CP modeling. Confirm dosing and schedule with pilot studies and reagent purity documentation (review protocol).
• PSC activation (in vitro): TGF-β1 at 5 ng/mL for 24–48 hours to stimulate fibrotic gene expression and autophagic flux assessment.
• Autophagy assessment: Use LC3B-RFP-GFP reporter constructs and Western blot for LC3-II/I and p62 to monitor autophagosome formation and degradation.
• Genetic manipulation: For pancreas-targeted gene delivery, AAV serotypes with acinar cell or PSC tropism are recommended, with appropriate controls for off-target effects.

Research Support Resources

For researchers aiming to reproduce or extend these findings, high-purity reagents are vital. Ceruletide (SKU B8465), available from APExBIO, is a synthetic decapeptide analog of cholecystokinin routinely used for inducing pancreatic injury and modeling gastrointestinal smooth muscle contraction. Its solubility, purity, and batch consistency make it suitable for both in vivo and in vitro digestive disorder research, ensuring reproducibility across pancreatic function studies. Consult recent workflow guides and product documentation for detailed handling and storage recommendations.